News & Updates

Show Multimedia Only

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

17 Mar 2025

Exposure to acetaminophen (paracetamol) may contribute to poor outcomes in patients with acute viral hepatitis (AVH)-related acute liver failure (ALF), suggests a study.

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

17 Mar 2025

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025 by

Individuals with a family history of colorectal cancer (CRC) are at greater risk of developing adenoma, nonadvanced adenoma (NAA), advanced adenoma (AA), and advanced neoplasia (AN), reveals a study.

Family history of CRC ups risk of adenoma, neoplasia

17 Mar 2025

$Upadacitinib for refractory CD safe, effective in real-world use$

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

In a real-world cohort of patients with highly refractory Crohn’s disease (CD), upadacitinib treatment prompted clinical response in most and steroid-free clinical remission in half, while having an acceptable safety profile.

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

12 Mar 2025 by

Among patients with gastric cancer and peritoneal metastasis, treatment with neoadjuvant intraperitoneal–systemic (NIPS) regimen, which consists of intraperitoneal (IP) and intravenous (IV) paclitaxel plus S-1, significantly improved overall survival (OS) compared with IV paclitaxel plus S-1 only (PS regimen), according to the DRAGON-01 trial presented at ASCO GI 2025.

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

12 Mar 2025

COVID-19 may leave lingering GI issues in children

10 Mar 2025 by

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

COVID-19 may leave lingering GI issues in children

10 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025

Leisure-time physical activity helps prevent hepatic steatosis

05 Mar 2025 by

Leisure-time physical activity (PA) offers protection against hepatic steatosis, with greater benefits seen among women and young people, suggests a study. Additionally, increasing leisure-time PA in men helps prevent liver fibrosis.

Leisure-time physical activity helps prevent hepatic steatosis

05 Mar 2025

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

Sarcopenic dysphagia in older adults: Multidisciplinary approach for prevention, diagnosis and management

04 Mar 2025 by

Sarcopenic dysphagia, which refers to difficulty swallowing caused by muscle loss, is an underrecognized, relatively new disease entity often seen in older adults. In an interview with MIMS Doctor, geriatrician Dr Tung-Wai Au Yeung of the Jockey Club Institute of Ageing, the Chinese University of Hong Kong, and dietitian Dr Terry Ho-Yan Ting in private practice discussed the causes and multidisciplinary approach to diagnosing, preventing and managing sarcopenic dysphagia, including nutritional support with protein supplementation and rehabilitation.

Sarcopenic dysphagia in older adults: Multidisciplinary approach for prevention, diagnosis and management

04 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

Family history of CRC ups risk of adenoma, neoplasia

Family history of CRC ups risk of adenoma, neoplasia

Upadacitinib for refractory CD safe, effective in real-world use

Upadacitinib for refractory CD safe, effective in real-world use

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

COVID-19 may leave lingering GI issues in children

COVID-19 may leave lingering GI issues in children

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Leisure-time physical activity helps prevent hepatic steatosis

Leisure-time physical activity helps prevent hepatic steatosis

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Sarcopenic dysphagia in older adults: Multidisciplinary approach for prevention, diagnosis and management

Sarcopenic dysphagia in older adults: Multidisciplinary approach for prevention, diagnosis and management